Article Contents ::
- 1 The Brand Name ONCOPLATIN-AQ Has Generic Salt :: Cisplatin
- 2 ONCOPLATIN-AQ Is From Company Sun Priced :: Rs. 86.9
- 3 ONCOPLATIN-AQ have Cisplatin is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ONCOPLATIN-AQ Has Generic Salt :: Cisplatin
ONCOPLATIN-AQ Is From Company Sun Priced :: Rs. 86.9
ONCOPLATIN-AQ have Cisplatin is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Cisplatin | INJ | Rs. 86.9 | 20ML |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 20ML |
| ONCOPLATIN-AQ | Sun | 10MG | 20ML | Rs. 86.9 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Sun :: ONCOPLATIN-AQ | Cisplatin | Anti Neoplastic Agents | Anti Neoplastic Agents |
Indications for Drugs ::
Lymphomas, Sarcomas, Carcinomas, Small cell lung cancer, Ovarian cancer, Germ cell tumors, Metastatic Testicular Tumors, Metastatic Ovarian Tumors, Advanced Bladder Cancer
Drug Dose ::
Adult: IV Metastatic ovarian cancer As monotherapy: 100 mg/m2 per cycle, given as a single dose once every 4 wk. For combination therapy w/ cyclophosphamide: 75-100 mg/m2 on day 1 of every 4-wk cycle. Metastatic testicular tumours 20 mg/m2/day for 5 days per cycle. Advanced bladder cancer 50-70 mg/m2 per cycle once every 3-4 wk.
Contraindication ::
Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation.
Drug Precautions ::
Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity.
Drug Side Effects ::
Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. Potentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities.
Pregnancy category ::
4
Drug Mode of Action ::
Cisplatin modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs e.g. fluorouracil. It has a narrow therapeutic margin and is highly toxic.
Drug Interactions ::
Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ?100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression. Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.
